Strategic partnerships CU Anschutz has active and growing collaboration with industry and medical centers, including Bayer, RefinedScience, Network Bio, and Oxford Medical Simulation, indicating openness to enterprise partnerships, joint research programs, and sponsored projects that can drive contract research, tech licensing, and capability outsourcing.

Clinical data potential Recent partnerships involve processing and linking single-cell multi-omic data with matched clinical data under IRB governance, signaling opportunities for data analytics services, bioinformatics platforms, and secure data infrastructure offerings for research and clinical trial work.

Healthcare innovation Active projects span nonhormonal therapies for GSM, osteoarthritis drug development, and clinical trial collaborations, suggesting demand for trial management software, patient recruitment tools, regulatory compliance services, and translational research support.

Tech stack leverage CU Anschutz already utilizes cloud and marketing platforms (AWS, Azure, Google Ads, Salesforce, HubSpot, iCIMS) and AI tools (OpenAI), indicating cross-sell opportunities for cloud optimization, data science consulting, AI/ML workflow solutions, and marketing automation enhancements.

Growth and leadership With revenue in the low to mid millions, a mid-sized graduate institution footprint, and recent leadership changes, there is potential for scalable training programs, executive education partnerships, and sponsored research initiatives that align with expanding institutional capabilities.